Takeda Pharmaceutical Company Limited [4502.T]
TOKYO, Mar 30 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) announced positive phase 3 clinical trial results for its TYK2 inhibitor, zasocitinib, showing significant improvements in skin symptoms for patients with moderate to severe plaque psoriasis. Approximately one-third of patients achieved clear skin or near-clear skin by week 16, surpassing placebo and apremilast groups.
The trials also showed a high PASI 75 achievement rate as early as four weeks, indicating sustained effectiveness. Over 60% of patients who continued treatment up to 40 weeks maintained improvements through week 60.
Zasocitinib demonstrated a favorable safety profile with no new adverse events reported. Takeda plans to file for regulatory approval with the FDA and other authorities in fiscal 2026.
The results are expected to support zasocitinib's potential as a leading oral therapy option for psoriasis patients seeking convenient daily dosing.
🟢 Confidence: High AI-translated content.